EGFR and neoplasm: Among the anti-EGFR therapeutic antibodies, some encouraging results have instead been obtained with Nimotuzumab, whose binding requires that EGFR is expressed at high density on the surface of the target cells, thus resulting in selective activity on EGFR-overexpressing tumor cells as compared to normal cells (115, 121).